We previously delineated genes whose promoters are hypomethylated and induced in hepatocellular carcinoma (HCC) patients. The purpose of this study was to establish the players that regulate these genes in liver cancer cells. We performed chromatin immunoprecipitation with methyl-CpG-binding domain protein 2 (MBD2), RNA polymerase II (RNA pol II), CCAAT/enhancerbinding protein alpha (CEBPA) antibodies and methylated DNA immunoprecipitation in HepG2 liver cancer cells treated with scrambled small interfering RNA (siRNA) and siRNA to MBD2 or CEBPA. We then hybridized DNA to microarrays spanning the entire coding sequences, introns and regulatory regions of several hundred HCC-hypomethylated genes. These analyses reveal that MBD2 binds a significant fraction of the hypomethylated genes, determines RNA pol II binding and DNA methylation state. MBD2 binding can result in promoter activation and hypomethylation or in repression. In activated target genes, MBD2 colocalizes with the transcription factor CEBPA, and MBD2 binding at these positions is reduced upon CEBPA depletion. Significant fraction of MBD2 effects on DNA methylation and transcription appears to be indirect since changes occur upon MBD2 depletion in genes where no MBD2 binding was detected. Our study delineates the rules governing the interaction of MBD2 with its targets and the consequences to RNA pol II binding and DNA methylation states. This has important implications for understanding the role of DNA methylation in cancer and targeting DNA methylation proteins in cancer therapy.
Introduction
Methylated DNA-binding proteins bind methylated DNA as well as unmethylated and active promoters as indicated by recent comprehensive chromatin immunoprecipitation (ChIP) sequencing studies (1) . A member of this family of proteins, methyl-CpG-binding domain protein 2 (MBD2), was shown previously to cause gene silencing of methylated promoters through recruitment of the NuRD complex (2) (3) (4) (5) ; however, the role of the NuRD complex in gene silencing by methylated DNA-binding proteins has recently been challenged (1) . Few other studies have shown that MBD2 could activate and cause demethylation of certain promoters (6) (7) (8) , particularly in cancer. Interestingly, consistent with these earlier observations, recent ChIP sequencing analysis of MBD2 in embryonic stem cells revealed a class of MBD2 target promoters that are unmethylated and active (1) . For example, inhibition of MBD2 results in silencing and hypermethylation of prometastatic genes such as urokinase-type plasminogen activator (PLAU) and matrix metallopeptidase 2 (MMP2) in breast and prostate cancer cell lines (9, 10) , and forced expression of MBD2 leads to demethylation of these genes in liver cells (11) . The mechanisms that determine whether MBD2 is targeted to sites where it has either repressive or activating functions are unknown. Understanding what defines whether a methylated promoter is silenced or demethylated and activated is critical for understanding how DNA methylation plays its physiological role as well as understanding the mechanisms behind the pathological activation of prometastatic genes in cancer.
Cancer offers the best example for a broad alteration in the DNA methylation state that involves hypomethylation and hypermethylation of different sets of genes with opposite roles in cancer progression (11) . Most of the previous studies looking at MBD2 function focused on few candidate genes and few selected candidate regions, thus the rules that switch MBD2 from a silencer of methylated genes to an activator of gene transcription remained unknown. To define the rules guiding MBD2 involvement in initiation of transcription and in DNA hypomethylation, it is critical to use a locus-wide comprehensive approach that spans entire gene bodies and their adjacent 5′ and 3′ sequences in a broad representation of genes that are demethylated in vivo in human patients. By reducing genomic representation to focus on molecular events that occur in tumors in humans, it is possible to perform a detailed and comprehensive analysis of a subset of gene loci, which would be infeasible if we examined all known genes in the entire genome. Such a high-content broad analysis of a limited set of gene loci enables identifying yet non-described regulatory and transcription start regions that reside outside known regulatory sequences.
In this study, we compared control human liver cancer cell line HepG2 and the same cells after depletion of MBD2 with small interfering RNA (siRNA) as a tractable cellular model of MBD2 binding in liver cancer. We designed custom high-density oligonucleotide arrays that correspond to the entire gene bodies and up to 12 kb upstream and 10 kb downstream of known transcription start site (TSS) within 284 genes shown to be demethylated in tumors from liver cancer patients (Supplementary Table S1A , available at Carcinogenesis Online) (11) . These human genomic regions that were printed on our array to cover the 284 genes demethylated in hepatocellular carcinoma (HCC) also contained 225 other neighboring genes (76 of this list were also hypomethylated in HCC patients including 44 that showed overexpression in tumors) (Supplementary Table S1A, available at Carcinogenesis Online). We compared ChIP-on-chip analyses with antibodies against MBD2 and RNA polymerase II (RNA pol II) carboxy terminal domain (CTD) phospho-Ser5, that is the RNA pol II form present at transcription onset points, and methylated DNA immunoprecipitation (MeDIP) analysis with an antibody against 5-methylcytosine using these custom arrays in HepG2 cells transfected with scrambled siRNA (siCtrl) and siRNA to MBD2 (siMBD2). MBD2-binding sites associated with activation of transcription onset and hypomethylation were highly enriched for motifs for Sp1 and CCAAT/enhancer-binding protein alpha (CEBPA). Interestingly, CEBPA has been shown to be overexpressed in HCC patients and to promote cell growth of HCC cells (12) . After depletion of CEBPA in HepG2 cells, we hybridized DNA to the same custom arrays in order to test whether and where CEBPA-binding sites colocalize with MBD2-binding sites. We validated the results by pyrosequencing and quantitative PCR (qPCR) using input and bound DNA. We confirmed changes in RNA pol II CTD phospho-Ser5, MBD2 and CEBPA occupancy after MBD2 or CEBPA depletion in another liver cancer cell line, SkHep1, and using other sets of siRNA to exclude the possibility of idiosyncrasy of either cell line or siRNA sequence.
These analyses allowed us to address a few major questions. First, we determined where MBD2 binds across the tested loci. Second, we determined whether MBD2 binding is required for occupancy of phosphorylated RNA pol II CTD phospho-Ser5 in certain transcription onset start sites and for blocking RNA pol II CTD phospho-Ser5 binding in other transcription start positions. Third, we evaluated whether MBD2 binding was required for maintaining a demethylated state at its binding sites. We then tested the hypothesis that binding of a transcription factor, CEBPA, delineated MBD2 role in recruitment of RNA pol II CTD phospho-Ser5 binding to start sites. The studies described below present a mechanism for the switching of MBD2 action from suppression of methylated DNA to promoter activation. This mechanism seems to play a critical role in inducing cancer cell invasiveness.
Materials and methods
Cell culture and transfection with siRNA Human HCC HepG2 and adenocarcinoma SkHep1 cells were purchased from American Tissue Culture Collection (HB8065 and HTB52, respectively) and were maintained in minimum essential medium (MEM; Gibco) supplemented with 2 mM glutamine (Sigma-Aldrich, St Louis, MO), 10% fetal bovine serum (Gibco), 1 U/ml penicillin and 1 µg/ml streptomycin (Gibco). Cells were grown in a humidified atmosphere of 5% carbon dioxide at 37°C. Twenty-four hour prior to siRNA treatment, cells were plated at a density of 4-6 × 10 5 per 10 cm tissue culture dish. The following siRNAs, obtained from Dharmacon, were used in this study: control siRNA (siCtrl, antisense strand: 5′-UCGCCUAGGCUGCCAAGGCUU-3′), human MBD2 siRNA (siMBD2, antisense strand: 5′-UUACUAGGCAUCAUCUUUCUU-3′; siMBD2-1, antisense strand: 5′-GGCCGGGCAAUCCAUCCUCUUUU-3′) and human CEBPA siRNA (siCEBPA, M-006422-03-0010; siCEBPA-2, antisense strand: 5′-UUGUCCACCGACUUCUUGGUU-3′). The cells were transfected with siRNA using lipofectamine RNAiMAX (Invitrogen) in serum-free Opti-MEM. Fifteen microliters of lipofectamine were incubated in 500 µl of Opti-MEM for 45 min at room temperature. siRNA was added to the Opti-MEMlipofectamine solution to a final concentration of 56 nM except siCEBPA-2 where 90 nM concentration was used. The mixture was incubated for 15 min at the same conditions; Opti-MEM was added to a final volume of 5 ml and was then added onto the plates. The transfection solution was removed from the cells and replaced with standard medium after 4 h. The cells were split 1:2 after 48 h and transfected again 24 h later. The transfection sequence was repeated three times. Inhibition of target genes was validated by qPCR and western blot analysis (see below and Supplementary Materials and methods, available at Carcinogenesis Online).
Viability, anchorage-independent growth and invasion assays
Cell viability was determined by trypan blue (Sigma-Aldrich) exclusion test. Cells were harvested after transfection with siRNA on days 3, 6 and 9. Following 3-5 min incubation with trypan blue, the viable cells were counted under the microscope.
To determine anchorage-independent growth on soft agar, an in vitro measure of oncogenesis (13) , 6000 live cells transfected with either siCtrl or siMBD2/siCEBPA were seeded into soft agar and plated in triplicate in a 6-well plate for 21 days as described previously (14) . The number of colonies (>10 cells per colony) in five random fields (×40) per well, throughout all planes of the triplicate wells, was counted under the microscope. The ability of treated cells to invade through extracellular matrix was evaluated by the Cell Invasion Assay Kit (Chemicon International). The kit utilizes a reconstituted basement membrane matrix of proteins derived from Engelbreth-HolmSwarm mouse tumor. Briefly, 50 000 cells resuspended in serum-free media were added to the inserts dipped in the lower chamber containing complete media. Following 24 h incubation at 37°C, invasive cells were stained and counted under the microscope.
RNA extraction and qPCR
Total RNA was isolated using TRIzol (Invitrogen, Life Technologies, Carlsbad, CA) according to the manufacturer's protocol. One microgram of total RNA served as a template for complementary DNA synthesis using 20 U avian myeloblastosis virus reverse transcriptase (Roche Diagnostics), as recommended by the manufacturer. The qPCR reaction was carried out in Light Cycler 480 machine (Roche) using 2 µl of complementary DNA, 400 nM forward and reverse primers, listed in Supplementary Table S1B, available at Carcinogenesis Online, and 10 µl of Light Cycler 480 SybrGreen I Master (Roche) in a final volume of 20 µl. Amplification was performed using the following conditions: denaturation at 95°C for 10 min, amplification for 60 cycles at 95°C for 10 s, annealing temperature for 10 s, 72°C for 10 s and final extension at 72°C for 10 min. Quantification was performed using a standard curve and analyzed by the Roche Light Cycler 480 software.
Pyrosequencing
Bisulfite conversion was performed as described previously (15) . Specific bisulfite converted promoter sequences were amplified with HotStar Taq DNA polymerase (Qiagen) using biotinylated primers listed in Supplementary  Table S1C , available at Carcinogenesis Online. The biotinylated DNA strands were pyrosequenced in the PyroMarkTMQ24 instrument (Biotage, Qiagen) as described previously (16) . Data were analyzed using PyroMarkTMQ24 software.
Methylated DNA immunoprecipitation and chromatin immunoprecipitation
Purified DNA from cells treated with siRNA was enriched for methylated DNA using the MeDIP protocol developed by Cedar's group (17) . Briefly, 2 µg of genomic DNA isolated from cancer cells was sonicated, precleared with sepharose beads and divided into input DNA and DNA sample incubated with anti-5-methylcytosine antibody (NA81; Calbiochem) overnight at 4°C. The next day, the unbound fraction was removed, and DNA bound to the beads was subjected to multiple salt washes. The bound fraction was then eluted and the antibodies were degraded by protease K treatment.
ChIP and double ChIP was performed as described previously (18, 19) . Briefly, 5 million cells were fixed with 1% formaldehyde for 15 min at 37°C in the presence of protease inhibitor (Complete; Roche). Fixed cells were then lysed and subjected to sonication. Each sample was precleared with protein G agarose and divided into three subsamples. One subsample was maintained as an input (input/bound = 1/9), the second subsample was incubated with anti-MBD2 sheep polyclonal antibody (07-198; Upstate-Millipore), anti-RNA pol II CTD phospho-Ser5 antibody (ab5408; Abcam) or anti-CEBPA goat polyclonal antibody (sc-9315; Santa-Cruz Biotechnology) and the third subsample was incubated with sheep, mouse or goat IgG non-specific antibody (negative control, sc-2717, sc-2025, sc-2020; Santa-Cruz Biotechnology) overnight at 4°C. The next day, the unbound fraction was removed, and DNA bound to the beads was subjected to multiple salt washes. The bound fractions were then eluted, and the antibodies were degraded by protease K treatment. For the double ChIP assay, 10 million HepG2 cells were fixed with 1% formaldehyde and divided into two equal samples. One sample was immunoprecipitated with anti-MBD2 antibody and subsequently with anti-CEBPA antibody, whereas the second sample was immunoprecipitated with anti-CEBPA antibody and then with anti-MBD2 antibody. Seventy percentage of a fraction bound to the first antibody was taken for immunoprecipitation with the second antibody after washing steps. The agarose beads with the bound DNA were dissociated from the first antibody, and DNA was eluted and incubated with the second antibody overnight at 4°C. The next steps were identical with the single ChIP protocol as described above.
Custom-designed methylation and ChIP microarrays
Following MeDIP and ChIP, the labeled input and bound DNA samples were hybridized to a custom-designed 60K microarray that contained probes covering the entire gene bodies sequence including all exons and introns and 12 kb upstream and 10 kb downstream of known TSS of 284 genes (Supplementary Table S1A , available at Carcinogenesis Online). These genes were chosen since they were hypomethylated and induced in liver cancer patients and/or hypomethylated in HepG2 cells according to our microarray data published previously (11) . The loci of these genes contained also 225 neighboring genes in either the 5′ upstream or downstream sequences of the genes that we had originally selected (76 of this list were also hypomethylated in HCC patients including 44 that showed overexpression in tumors) (Supplementary Table  S1A , available at Carcinogenesis Online). All steps of hybridization, washing and scanning were performed following the Agilent protocol for ChIP-onchip analysis. The methods for statistical analysis of methylation and ChIP microarrays are detailed in Supplementary Materials and methods, available at Carcinogenesis Online. The results were validated by quantitative MeDIP and quantitative ChIP where methylated immunoprecipitated DNA or ChIP DNA was used as a template for qPCR. Twenty-five nanograms of bound and input DNA was used as a starting material in all conditions. Level of methylation was expressed as bound/input, whereas level of protein binding was expressed as (bound IgG)/input. Negative values were presented as zero. The double ChIP validation was performed as described previously (19 
Results
The landscape of MBD2 binding to target genes in HepG2 HCC cells Our previous delineation of the landscape of DNA methylation in liver cancer has revealed a group of 230 gene promoters that were hypomethylated and whose expression was induced in HCC in comparison with the adjacent tissue in liver cancer patients (11) . Previous data suggested that MBD2 is overexpressed in liver cancer and that forced expression of MBD2 in normal primary epithelial liver cells could lead to demethylation of several of the genes that are demethylated in HCC tumors (11) . We reasoned, therefore, that liver cancer could serve as a good model for dissecting the molecular factors that define the role of MBD2 in induction of transcriptional onset. Since delineating these mechanisms is not feasible in tumors in vivo, we used HepG2 HCC cell line as a tractable cellular model. As MBD2 binding might occur outside the immediate region surrounding the known TSSs and in order to obtain a broad and unbiased delineation of the epigenetic relationships that regulate MBD2 action, we tiled the entire coding and intronic sequence as well as 12 kb 5′ and 10 kb 3′ regions of 284 genes that are demethylated in HCC and/or HepG2 (Supplementary  Table S1A , available at Carcinogenesis Online). Since we tiled a broad sequence upstream and downstream of the 284 genes, our array also included 225 other genes (Supplementary Table S1A , available at Carcinogenesis Online). We first performed ChIP with antibodies directed against MBD2 on HepG2 cells treated with either siCtrl or siMBD2. In order to delineate high confidence MBD2-binding sites in HepG2 cells, we subtracted the background binding detected in MBD2-depleted cells [log 2 (fold difference) > 0.5, False Discovery Rate < 0.2]. Our assay revealed 237 MBD2-binding sites located in 102 genes that were demethylated in tumor samples and 37 other genes that were in their proximity (Supplementary Table S2A , available at Carcinogenesis Online). Binding peaked around known TSS (117 binding sites within promoters) consistent with a link between MBD2 binding and transcription initiation ( Figure 1A ). However, binding was not limited to known TSS and was detected across introns (103 sites), exons (9 sites) and intergenic regions (8 sites) (column P in Supplementary Table S2A , available at Carcinogenesis Online; Figure 1B ). Several of these sites outside known TSS might be new MBD2-dependent TSS as will be discussed below. Binding of MBD2 occurs at discrete strategic positions across specific 139 genes.
Impact of MBD2 depletion on RNA pol II CTD phospho-Ser5
binding MBD2 binding at several TSS is consistent with a possible role for MBD2 in transcription onset. Phosphorylation of RNA pol II CTD at serine 5 indicates transition from initiation to elongation, when CTD remains phosphorylated at serine 5 at the 5′ of an actively transcribed gene (20) . To test the hypothesis that MBD2 plays a role in transcription onset, we mapped occupancy of RNA pol II CTD phosphoSer5 in our selected gene loci in HepG2 cells under either control or MBD2-depleted conditions using ChIP with anti-RNA pol II CTD phospho-Ser5 antibody and hybridization to our custom oligonucleotide array. It is apparent from this detailed high-density analysis that MBD2 has a dual impact on transcription onset in liver cancer cells since we detected both a decrease in RNA pol II CTD phospho-Ser5 binding (1463 sites within 343 genes) and an increased binding (1385 sites within 372 genes) (Supplementary Table S3A and B, available at Carcinogenesis Online). We define these sites as MBD2-dependent RNA pol II CTD phospho-Ser5-binding sites. MBD2 is then associated with both activation and suppression of transcription onset. Interestingly, many genes contain both increased and decreased RNA pol II CTD phospho-Ser5 binding in MBD2-depleted cells, suggesting a complex regulation of different RNA pol II transcription initiation positions in the same gene by MBD2. Overall MBD2 depletion results in a reduction in RNA pol II CTD phospho-Ser5-binding sites in genes that are demethylated in either liver cancer, HepG2 cells or both (see columns L and M in Supplementary Table S3A, available at Carcinogenesis Online). This supports the hypothesis that MBD2 is involved in triggering transcription onset of these demethylated genes in HCC.
The analysis of the overlap between MBD2-binding sites and MBD2-dependent RNA pol II CTD phospho-Ser5-binding positions revealed that MBD2 binds in the immediate proximity of 116 RNA pol II CTD phospho-Ser5 MBD2-dependent positions in 96 different genes. We consider these genes as 'MBD2 direct targets' in HepG2 liver cancer cells. In 87 of these genes (98 binding sites), RNA pol II CTD phospho-Ser5 binding is reduced upon MBD2 depletion (activated in the presence of MBD2), and in 15 genes (18 binding sites), it is increased (suppressed in the presence of MBD2) (Supplementary  Table S2B There is a strong statistical correlation between MBD2-binding positions and differential RNA pol II CTD phospho-Ser5 occupancy in response to MBD2 depletion (P = 1.22E-7, Fisher's exact test), supporting a critical role for MBD2 in delineating transcription onset. MBD2 depletion results in a shift in transcription onset positions, which could potentially result in different 5′ variants of the transcript expressed by the same gene. In 33 of the MBD2 direct target genes, there are both RNA pol II CTD phospho-Ser5-binding sites that increase in binding as well as those that decrease in response to MBD2 depletion (see column O in Supplementary Table S2B and C, available at Carcinogenesis Online: 'RNA pol II shift-different transcripts'). Furthermore, a certain fraction of MBD2-binding sites (121 corresponding to 78 genes) are located in positions that could not be physically linked with MBD2-dependent RNA pol II CTD phospho-Ser5-binding sites, and they are found in promoters (58 binding sites), introns (57 binding sites), exons (4 binding sites) and intergenic regions (2 binding sites) (column J in Supplementary Table S2A , available at Carcinogenesis Online). Although these MBD2-binding sites are not in physical juxtaposition with MBD2-dependent RNA pol II CTD phospho-Ser5-binding sites, it is nevertheless possible that MBD2 binding at these sites acts in cis on distant MBD2-dependent RNA pol II positions within the same genes. Indeed, 74 out of 78 genes that bind MBD2 also contained an MBD2-dependent RNA pol II position at a distant location.
MBD2 binding, transcription onset and state of DNA methylation
We used MeDIP analysis and hybridization to the same customdesigned microarrays to define the impact of MBD2 depletion on the state of DNA methylation and to test the correlation between depletion of MBD2, changes in DNA methylation and transcription onset. Depletion of MBD2 resulted in both increase and decrease in DNA methylation at different positions (Supplementary Table S4 , available at Carcinogenesis Online; Table I ). Overall, we found 361 differentially methylated sites within 179 genes where 190 sites were hypermethylated and 171 were hypomethylated (Supplementary Table S4 , available at Carcinogenesis Online). A total of 166 out of 190 hypermethylated binding sites were positioned in genes that were found to be hypomethylated in liver cancer in patients and/or HepG2 cells, supporting a role for MBD2 in maintaining their hypomethylated state (Supplementary Table S4 , available at Carcinogenesis Online).
There was a strong statistical relationship between MBD2 binding and changes in DNA methylation (P = 1.37E-5, Fisher's exact test; Table I ). Forty-one of significantly differentially methylated sites were associated with MBD2 binding at the same position, indicating that the rest of the changes in DNA methylation in response to MBD2 depletion are 'indirect' and are perhaps mediated by distant MBD2 Analysis. Right-tailed Fisher's exact test was used to calculate a P value determining the probability that each pathway assigned to that data set is due to chance alone. (E and F) Venn diagram showing overlap between the presence of MBD2-binding sites and (E) transcription onset sites that exhibit DNA hypermethylation and decreased RNA pol II CTD phospho-Ser5 binding upon MBD2 depletion in HepG2 cells and (F) TSSs that exhibit DNA hypomethylation and increased RNA pol II CTD phospho-Ser5 binding after MBD2 depletion in HepG2 cells. Statistical significance of overlaps as determined by Fisher's exact test is listed in Table I. interactions (column G in Supplementary Table S2A , available at Carcinogenesis Online). Thirty-six out of the 41 direct MBD2 targets were hypermethylated in response to MBD2 depletion, whereas only 5 were hypomethylated (Table I) . RNA pol II CTD phosphoSer5 binding decreased in the majority of 36 hypermethylated direct targets with only three events of increased binding, supporting a role for MBD2 in the active state of these genes ( Figure 1E and F) . Among five hypomethylated genes, only one gene showed increased RNA pol II binding ( Figure 1E and F) .
MBD2 binding and transcription factor occupancy
MBD2 is a methylated DNA-binding protein that recognizes methylated CpG sequences with limited additional sequence discrimination and is currently used as a method for detecting genome-wide DNA methylation profiles (1, 21) . What targets MBD2 to specific sequences and what defines the consequences of the interaction between MBD2 and its targets for DNA methylation and transcription onset is unknown. We hypothesized that different transcription factors would target MBD2 to specific positions in the genome and that the identity of interacting transcription factors would determine the consequences of this interaction for DNA methylation and transcription onset. We computed putative transcription factor-binding elements within MBD2-binding sites using TransFac software. Sp1 and CEBPA were found to be the most enriched transcription factors within the MBD2-binding sites in our selection of target genes (70% of MBD2-binding sites contain a putative CEBPA site; Figure 2A ). CEBPA is a liver-specific transcription factor involved in regulation of hepatocyte proliferation and differentiation that is induced in our group of HCC patients ( Figure 2B ) and was shown previously to be overexpressed in HCC patients and to promote cell growth of HCC cells (12) . We, therefore, delineated the binding targets of CEBPA in our target genes using ChIP analysis of either control or siCEBPAtreated HepG2 cells and hybridization to our custom microarray. High confidence CEBPA-binding sites were computed after subtraction of the background binding in the CEBPA-depleted cells. There are 1601 CEBPA-binding sites in the gene set that we had analyzed. A high fraction of these sites is colocalized with transcription onset sites that are either activated (195) or suppressed (305) in response to MBD2 depletion (Table I; Supplementary Table S5 , available at Carcinogenesis Online). There is a very strong relationship between MBD2-dependent transcription onset as defined by changes in RNA pol II CTD phospho-Ser5 occupancy in response to MBD2 depletion and presence of CEBPA-binding sites (P = 2.83E-48, Fisher's exact test). It strongly indicates that CEBPA is implicated in mediating MBD2-dependent transcription onset. However, a significant fraction of these effects does not involve 'direct' MBD2 interaction with the transcription start positions in the selected genes, as MBD2-binding sites are present only in 70 out of 500 transcription onset sites that colocalize with CEBPA binding (see columns H and J in Supplementary Table S5, available at Carcinogenesis Online). CEBPA might, therefore, be also involved in the 'indirect' effects of MBD2 on transcription onset, mediated by MBD2 activity on distant genomic targets. An alternative hypothesis is that these are weaker MBD2-binding sites that were not detected in our assay. In any case, this line of experiments strongly implicates CEBPA in MBD2 mechanisms of action. The functional analysis of cell growth, anchorage independent growth and cell invasiveness upon CEBPA depletion in HepG2 cells further enforces this implication. CEBPA depletion, similarly to MBD2 knockdown, decreases cancer cell growth ( Figure 2D and E), migration through the extracellular matrix ( Figure 2F ) and colony formation in soft agar ( Figure 2G ). Importantly, using another set of siCEBPA, we observed similar inhibitory effects on HepG2 and SkHep1 cancer cell growth as shown in Supplementary Figure S3E , available at Carcinogenesis Online.
A total of 113 CEBPA-binding sites colocalize with MBD2 binding, and a significant fraction of these sites (70) (RNA pol II CTD phospho-Ser5 binding) that are suppressed and hypermethylated upon MBD2 depletion ( Figure 2C ). Thus, CEBPA is present in 'direct' targets of MBD2 where MBD2 plays a role in activation of transcription onset and demethylation as indicated by hypermethylation and loss of RNA pol II binding after MBD2 depletion (Supplementary Table S6 , available at Carcinogenesis Online).
Representatives of this group of genes are illustrated in the microarray tracks in Supplementary Figure S1, Table S6 , available at Carcinogenesis Online) constitute MBD2-activated direct targets that are hypomethylated and active when MBD2 and CEBPA are present in their regulatory regions (note that CEBPA binding was present but not statistically significant within three of these genes). In contrast, suppressed MBD2 direct targets (Supplementary Table S2C , available at Carcinogenesis Online) are silenced when binding MBD2 mostly without CEBPA presence (CEBPA binding was identified only in two of these genes). Statistical significance of overlaps as determined by Fisher's exact test is listed in Table I . (D and E) CEBPA (D) and MBD2 (E) expression level quantified by qPCR after first (I, day 3), second (II, day 6) and third (III, day 9) transfection and by western blot after third transfection with siCtrl or siCEBPA/siMBD2. Effects of CEBPA (D) and MBD2 (E) depletion on cell growth after each transfection. (F and G) Effect on cell invasion and anchorage-independent growth as measured by Boyden chamber invasion and soft agar assays, respectively, as described in Materials and methods, after third transfection with siRNA. The results demonstrating effects of MBD2 depletion were adapted from Stefanska et al. (11) . All results represent mean ± SD of two or three independent experiments measured in triplicate, *P < 0.05, **P < 0.01, ***P < 0.001.
occupancy of RNA pol II CTD phospho-Ser5 at the same position (Supplementary Table S2C , available at Carcinogenesis Online). As mentioned before, MBD2 could have opposite effects on transcription onset in different transcription start positions residing within the same gene. For example, CTNNA2 transcript variant 1, which is occupied with CEBPA, is activated by MBD2, whereas transcript variant 3 is suppressed by MBD2 (Supplementary Figure S1 , available at Carcinogenesis Online).
Properties of MBD2-binding sites
Our study revealed a high-density map of MBD2-binding sites covering the entire span of several hundred gene loci in liver cancer cells. MBD2-binding sites that 'positively' regulate transcription onset (defined by decreased RNA pol II binding after MBD2 depletion) are distributed equally between −2 and +4 kb relative to known TSS, whereas MBD2 binding that 'negatively' regulates transcription (defined by increased RNA pol II binding after MBD2 depletion) peaks at −2 kb and mostly at +4 kb ( Figure 1A ; P = 0.03, Fisher's exact test). In 57 sites shown in the Supplementary Table S7 , available at Carcinogenesis Online, MBD2 binds in regions located further than 3 kb away from known TSS and overlaps with RNA pol II CTD phospho-Ser5 sites, indicating new putative MBD2-dependent transcription onset positions that were not described previously. For instance, in MMP13, we found an MBD2-dependent RNA pol II CTD phospho-Ser5 peak 7 kb upstream of the documented TSS, suggesting that MBD2 may induce a novel yet unidentified MMP13 transcript variant ( Figure 3A) , alternatively it might form a 3D interaction with the known TSS. Recent whole-genome studies indicate that differentially methylated regions are located predominantly in CpG shores and CpG All results represent mean ± SD of three determinations in either two or three independent experiments; *P < 0.05, **P < 0.01, ***P < 0.001.
shelves that are 2 and 4 kb away from CpG islands, respectively (22) . We, therefore, tested whether there was a preference for MBD2-binding sites for regions with certain CpG density and whether there was a difference between transcription onset positions 'positively' and 'negatively' regulated by MBD2. All MBD2-binding sites at intervals of 1000 bp were divided into three CpG density groups: high (HCP), intermediate (ICP) and low (LCP) (23, 24) . MBD2 occupancy is not different from expected taking into account all regions tiled on the array. Our analysis indicates that MBD2 has no preference in binding to regions of certain CpG density regardless of whether a gene is activated or suppressed.
We then performed an Ingenuity Pathway Analysis to examine whether genes that are activated (87 genes encompassing 98 MBD2-binding sites) or suppressed (15 genes encompassing 18 MBD2-binding sites) by MBD2 fall under different functional gene categories (five suppressed targets are also listed in the activated targets due to differential MBD2-dependent regulation of their transcripts). We were able to find differences in top biological processes and signaling pathways characteristic for either activated or suppressed MBD2 direct targets (Table II ; Figure 1C and D) . Genes activated by MBD2 (show a reduction in RNA pol II binding upon MBD2 depletion) are implicated in cancer, gastrointestinal and hepatic system disease, cell death and survival, connective tissue development, digestive and hepatic system development and function; elements that are critical for liver function and cell survival and motility. Various well-established cancer signaling pathways, such as ovarian cancer and glioblastoma signaling, pancreatic adenocarcinoma, colorectal cancer metastasis, WNT and JAK2 pathways or hepatic stellate cell activation and liver fibrogenesis, events that culminate in cirrhosis and liver cancer (25) , are upregulated by MBD2.
On the other hand, genes that are suppressed by MBD2 play a role in neurological disease and nervous system development, cellular growth and proliferation, protein kinase A and G protein signaling, ephrin B signaling that regulates cell migration and segmentation, stem cell differentiation, formation of tissue boundaries, and angiogenesis (26) . MBD2-activated target genes are involved in promitogenic and prometastatic processes as well as functions highly relevant to liver and liver tumorigenesis. Although suppressed targets are also linked to cancer and contain several genes that were found to be hypomethylated in HCC patients (Supplementary Table  S2C , available at Carcinogenesis Online), we need to take into account the possibility of different roles of these genes depending on transcript variants. Twelve of the suppressed targets (show an increase in RNA pol II upon MBD2 depletion) contain MBD2-binding site within introns and exons, implying regulation of alternative transcripts.
Validation of MBD2-dependent demethylation and activation of transcription onset
We then tested the hypothesis that MBD2 is responsible for hypomethylation and initiation of transcription of a fraction of genes that were found to be demethylated in vivo in HCC tumors (11) . Seventy-six of the direct MBD2 targets and 319 of the indirect targets were demethylated in HCC patients (Supplementary Table  S8 , available at Carcinogenesis Online). Our array has delineated a group of 22 transcription onset regions that are 'direct' MBD2 transcriptional onset activation and demethylation targets; depletion of MBD2 results in their silencing and remethylation (see Supplementary Figure S1 , available at Carcinogenesis Online, for examples of the array tracks and Supplementary Table S6, available at Carcinogenesis Online, for the gene list). Six regions containing significant or strong MBD2-binding sites, reduced RNA pol II CTD phospho-Ser5 binding and increased DNA methylation upon depletion of MBD2 were chosen for validation of the microarray analyses: MMP13, ORC6L, RASAL2, S100A4 (Figure 3 ), PPARG and ENPP4 (Supplementary Figure S2A and B, available at Carcinogenesis Online). Using qPCR with primers flanking the identified regions (see physical maps in Figure 3 and Supplementary Figure S2A and B, available at Carcinogenesis Online), we quantified the abundance of these regions in anti-MBD2 ChIPs prepared from HepG2 cells treated with siCtrl or siMBD2; we confirmed MBD2 binding in control HepG2 and reduced MBD2 binding upon MBD2 depletion to all six regions. The same regions were hypermethylated in response to MBD2 depletion as measured by pyrosequencing of these regions (Figure 3 ; Supplementary Figure  S2A and B, available at Carcinogenesis Online). Transcription onset positions in all six regions and their inhibition in response to MBD2 depletion were confirmed by qPCR quantification of abundance of the regions in RNA pol II CTD phospho-Ser5 ChIPs. In summary, we have validated six out of six genes that were selected for validation, illustrating the robustness of our analysis of the microarray data. Interestingly, MBD2-binding sites are located 1-3 kb away from known TSS for several tested genes such as PPARG, ORC6L and ENPP4, suggesting that MBD2 may possibly govern transcription of new variants as discussed above.
CEBPA is required for MBD2 binding to regulatory regions of activated targets
The microarray analysis of CEBPA binding suggested that co-occupancy of CEBPA and MBD2 is associated with transcription onset activation and hypomethylation (see Figure 2C and Table I for statistical tests of these interactions). Out of 113 sites with MBD2 and CEBPA bindings, 67 sites show decreased RNA pol II CTD phosphoSer5 occupancy upon MBD2 depletion, and 19 out of these 67 sites become hypermethylated in response to MBD2 depletion. These overlaps are highly statistically significant as measured by Fisher's exact test (Table I) . In contrast, only 3 out of 113 MBD2-CEBPA cobinding sites show an increase in RNA pol II CTD phospho-Ser5 binding upon MBD2 depletion with one site hypermethylated. We, Right-tailed Fisher's exact test was used to calculate a P value determining the probability that each biological function and/or disease assigned to that data set is due to chance alone. These data are consistent with the supposition that binding of a transcription factor CEBPA precedes and conditions MBD2 binding to this class of TSSs, which in turn sustains hypomethylation and onset of transcription. These data demonstrate that transcription factors such as CEBPA are required for MBD2 binding to its activated targets. Interestingly, CEBPA binding to MMP13 and S100A4 promoters increases after MBD2 depletion ( Figure 4A and D) , which enforces the primary role of CEBPA in CEBPA-MBD2 colocalization of these promoters. It is possible that the promoters are more enriched in CEBPA in either compensation to absence of MBD2 or perhaps due to MBD2 normally limiting recruitment of CEBPA.
To determine whether MBD2 and CEBPA are physically cobinding the same molecules of DNA, we performed double ChIP assays. HepG2 cells were fixed with formaldehyde and divided into two samples that were subjected to immunoprecipitation first with MBD2 and then with CEBPA antibodies or first with CEBPA and then with MBD2 as described in Materials and methods. The analysis was performed as described previously (19) and shows that promoters of all six genes are physically co-occupied by MBD2 and CEBPA in HepG2 cells ( Figure 4E; Supplementary Figure S2C , available at Carcinogenesis Online). Regardless if chromatin was first immunoprecipitated with MBD2 or with CEBPA antibody, binding of both proteins to the same molecules of promoter DNA was validated. MBD2 and CEBPA are enriched on and fully co-occupy MMP13 promoter; higher or equal levels of enrichment than those of single ChIP are seen regardless of the order of the two immunoprecipitations ( Figure 4E , white and pattern filled bars). The enrichment on promoters of ORC6L, RASAL2, S100A4 (Figure 4E ), PPARG and ENPP4 (Supplementary Figure  S2C , available at Carcinogenesis Online) is different between the two double ChIPs (white versus pattern filled bars). It suggests that MBD2 and CEBPA partially co-occupy these promoters. Interestingly, a higher level of enrichment is observed with MBD2/CEBPA double ChIP (white bars) than with CEBPA/MBD2 ChIP (pattern filled bars) for all four genes except S100A4. It implies that CEBPA binds promoters of ORC6L, RASAL2, PPARG and ENPP4, and MBD2 binds a fraction of the CEBPA-bound promoters. It is consistent with the conclusions derived from siCEBPA knockdown experiment that these sequences are primarily targeted by CEBPA and then by MBD2, and that MBD2 binding in these promoters requires CEBPA, but CEBPA binding does not require MBD2. For S100A4, the enrichment is higher with CEBPA/MBD2 ChIP than MBD2/CEBPA, suggesting that a large fraction of CEBPA-bound promoter also binds MBD2.
To rule out that the observed effects are cell line or siRNA sequence specific, we used another set of siRNAs and performed The analysis was performed as described previously (19) . Binding of the first protein to the indicated promoter was determined by qPCR with the appropriate primers and expressed as (bound A-IgG A)/input (where A means immunoprecipitation with the first antibody) and binding of the second protein was calculated as (bound B-IgG B)/input (where B means subsequent immunoprecipitation with the second antibody). All results represent mean ± SD of two or three independent experiments, measured in triplicate; *P < 0.05; **P < 0.01, ***P < 0.001.
MBD2 and CEBPA depletion in HepG2 and SkHep1 liver cancer cells followed by ChIP with anti-RNA pol II CTD phospho-Ser5 and anti-MBD2 antibodies, respectively. As shown in Supplementary  Figure S3A -D, available at Carcinogenesis Online, MBD2 binding decreases in both HepG2 and SkHep1 cells after depletion of CEBPA with an independent set of siRNA sequences. In the same fragments, we detected attenuation of RNA pol II CTD phosphoSer5 binding after MBD2 depletion using another set of siRNA in both cell lines. These data demonstrate that the results of our study are not an idiosyncrasy of the HepG2 cell line or the siRNA sequence used and provide high confidence that we were measuring effects of MBD2 and CEBPA depletion on RNA pol II binding and MBD2 binding.
Discussion
MBD2 is a well-established 'reader' of the methylation signal that leads to silencing of methylated genes through recruitment of chromatin modifying proteins (2, 4, 27) . However, MBD2 was shown previously to be also implicated in activation of several prometastatic genes in breast (28) , prostate (10) and liver cancer (11) . Since most of the reports to date are derived from looking at a few candidates and at a limited number of regulatory regions, our understanding of regulation of transcriptional activation/repression by MBD2 has been anecdotal and seemingly contradictory. By biasing the analysis to limited regions, these previous results provide a limited and restricted view of MBD2 function. In this study, we utilized a broad representation of genes that are demethylated and activated in liver cancer and examined the entire sequence of the bodies of the genes and their 5′ upstream and 3′ downstream regions. Using this approach, we were able to examine the possibility that important regulation by MBD2 occurs outside known TSS and that MBD2 regulates transcription onset in new and different positions.
We used a human liver cancer cell line HepG2 as a model to test whether there is a functional relationship between MBD2 and transcription onset using siRNA depletion strategies. Although we were using a cell line, we maintained the clinical relevance of our study by focusing on a few hundred genes that we have shown previously to be altered in human liver cancer patients. Using MBD2-depleted cells allowed us to subtract background binding and to derive high confidence MBD2-binding sites. To determine the relationship between MBD2 and transcriptional onset, we delineated across the same genomic regions the occupancy of RNA pol II CTD phosphoSer5, an RNA pol II modification that is found only in transcription onset positions in the genome (20) . This approach allows us to define how MBD2 affects promoter activation in contrast to Affymetrix arrays or qPCR, which measure steady state of messenger RNA, which is far downstream to gene activation and is a sum of multiple intermediary steps from splicing to RNA transport and messenger RNA stability. By comparing the binding sites of MBD2 and RNA pol II CTD phospho-Ser5, we identified MBD2-binding sites that were juxtaposed with transcription onset positions. By comparing RNA pol II CTD phospho-Ser5 occupancy under conditions of MBD2 depletion with control conditions, we were able to delineate transcription onset sites that are functionally dependent on MBD2. Using a methylation analysis approach (MeDIP) that utilized identical arrays for hybridization, we were able to juxtapose MBD2 binding, MBD2-dependent DNA methylation states and transcription onset positions.
This analysis has provided for the first time a comprehensive locus-wide understanding of the relationship between MBD2, DNA methylation and transcription onset in a set of several hundred genes that are epigenetically programmed in human liver cancer patients. First, our overall analysis shows a strong statistically significant relationship between MBD2 binding, transcription onset and DNA methylation states (Table I) . Second, MBD2 affects transcription in multiple ways, and these effects could target several transcription onset positions across a gene away from common TSS. This multimodal action of MBD2 can explain the contradictions noted in previous studies that have examined single genes, single or common messenger RNA variants and single or few candidate regulatory regions. Third, MBD2 affects transcription onset through direct binding of transcription onset regions as well as indirectly in trans through binding other positions perhaps across other genes or regulatory regions within the same genes as seen, for example, for KIF23 transcript variant 2, WNT2B transcript variant 2 and RASAL2 transcript variant 1 (Supplementary Figure  S1 , available at Carcinogenesis Online). Fourth, a large number of transcription onset sites (2732 sites corresponding to 439 genes) are altered by MBD2 depletion but do not have an MBD2-binding site. Thus, MBD2 seems to control a wide network of genes, and only less than a quarter of these genes (96 genes) are turned on/ off by direct interaction (Supplementary Table S2B and C, available at Carcinogenesis Online). It is possible, however, that some MBD2-binding sites that exist in vivo were not detected by the standard ChIP assay that we have used, but it is highly unlikely that all these binding sites were missed. A comprehensive analysis of the entire transcriptome in liver cancer cells under conditions of MBD2 depletion would reveal the regulatory cascade controlled by MBD2. Fifth, MBD2 defines not only the overall expression of a gene but also choice of transcription onset positions within the gene. In CTNNA2 for example, MBD2 depletion results in increase in RNA pol II CTD phospho-Ser5 occupancy at position 3 (transcript variant 3) and decrease in position 1 (transcript variant 1) (Supplementary Figure S1 , available at Carcinogenesis Online). This implies that in untreated HepG2 cells, MBD2 suppresses position 3 and activates position 1. This could serve as a mechanism for transcription variant choice that could alter the biological output. Presence of MBD2 is critical for liver cancer cell growth and invasiveness but not for normal cells as shown previously (11) . This might be partially mediated not just by overall expression differences but also by transcription variant choices, although future experiments are required to test this hypothesis. It must be noted, however, that some of the RNA pol II CTD phospho-Ser5-binding sites that were detected in our study represent multiple touch points of RNA pol II phospho-Ser5 initiation complex. Nevertheless, the positions of interaction changed in response to MBD2 depletion, suggesting that in any case, the transcription initiation complex position was altered by depletion of MBD2. The fact that we have revealed multiple transcription onset sites in gene loci that were selected for our arrays could explain why although these genes were selected for their induction of overall expression in liver cancer as determined by Affymetrix expression arrays, an examination of all the transcription onset sites nested in these genes reveals a more complex picture of regulation by MBD2.
Sixth, MBD2 depletion results in a broad change in DNA methylation in both directions, supporting the hypothesis that MBD2 is not just a 'reader' of the DNA methylation state but also participates in maintaining that state. These changes in DNA methylation are not limited to MBD2-binding sites (320 of the 361 methylation changes occur in regions that do not reveal MBD2 binding; see Supplementary  Table S4 , available at Carcinogenesis Online), suggesting that MBD2 affects DNA methylation states similar to transcription both 'directly' and 'indirectly' through a cascade of regulatory events. Thirty-six out of the 41 alterations in DNA methylation in response to MBD2 depletion that occur at MBD2-binding sites result in increased methylation consistent with the hypothesis that MBD2 is required for maintaining a demethylated state. Seventh, increased DNA methylation that occurs in response to MBD2 depletion is strongly associated with juxtaposed decrease in RNA pol II CTD phospho-Ser5 occupancy (P = 3.1E-4, Fisher's exact test; Table I ), supporting the hypothesis that these changes in transcription onset following MBD2 depletion are mediated in part through changes in DNA methylation. On the contrary, the relationship between decreased DNA methylation and increased RNA pol II CTD phospho-Ser5 binding after MBD2 depletion was not statistically significant (P = 0.28, Fisher's exact test; Table I ). Eighth, transcription factors such as CEBPA colocalizes with MBD2 at MBD2 targets of demethylation and transcriptional activation (Figure 4; Supplementary Figures S2C, S3C and D, available at Carcinogenesis Online).
Although MBD2 has widespread impact on transcription onset positions (Supplementary Table S3A and B, available at Carcinogenesis Online), the primary effects are plausibly mediated through direct binding to its targets at transcriptional start sites. We have delineated in our study 116 MBD2-binding sites whose depletion is associated with changes in RNA transcription onset (Supplementary Table S2B and C, available at Carcinogenesis Online). The majority of the direct effects of MBD2 (98 binding sites corresponding to 87 genes) result in increase in transcription onset (reduced RNA pol II occupancy after MBD2 depletion, see Supplementary Table S2B , available at Carcinogenesis Online; Table I ), which is consistent with the hypothesis that MBD2 coordinates a significant fraction of the induced genes in liver cancer. MBD2 depletion results in increased DNA methylation in 21 of these activated direct targets of MBD2 (22 binding sites), with only two events of decreased DNA methylation, which supports the conclusion that MBD2 maintains their demethylated state. A large fraction of these promoters (19 out of 22) contained CEBPA-binding sites (Supplementary Table S6 , available at Carcinogenesis Online). Overall, we identified 113 CEBPA-binding sites that coincide with MBD2 (Table I indicates The role of MBD2 in epigenetic regulation of gene expression has been controversial with multiple reports, suggesting that MBD2 participates in silencing of methylated genes (4, 5, 29, 30) and others claiming that MBD2 activates gene demethylation and expression (6) (7) (8) 31) . We have previously suggested that 'promoter-specific' effects of MBD2 (7) could explain this contradiction. Our data presented here supports this claim. The role of MBD2 in promotion of cancer cell growth and metastatic properties might be linked to both demethylation and activation of prometastatic genes (10, 11, 28) and hypermethylation and suppression of tumor suppressor genes (32) . Our data derived from concurrent locus-wide analysis of MBD2 binding to 509 genes (see Supplementary Table S1A , available at Carcinogenesis Online) provide strong evidence for the multimodal action of MBD2 in controlling gene expression and DNA methylation in liver cancer and propose that co-occupancy of certain transcription factors defines the consequences of MBD2 actions on TSSs. Recruitment by transcription factors such as CEBPA might define which transcription start positions will be activated and maintained demethylated by MBD2. Although our data that are based on MBD2 depletion experiments could only provide evidence for the requirement for MBD2 in maintaining the transcriptionally active and demethylated state, we have shown previously that forced expression of MBD2 could cause gene activation and demethylation in liver cells (11) . CEBPA is, however, not the only transcription factor involved in delineating MBD2 transcription activity since not all TSSs that require MBD2 for activation and demethylation are bound by CEBPA. Future studies are required to identify additional transcription factors that are involved in targeting MBD2 to maintain genes active and demethylated or suppressed and hypermethylated. Interestingly, a recent study on targeting principles of the MBD protein family reports MBD2 binding to both methylated-suppressed and unmethylated-active regulatory regions where binding of MBD2 to transcriptionally active sites in embryonic stem cells is mediated by the chromatin remodeling NuRD complex (1) .
Our data provide the first set of concepts explaining the coordinated activation and demethylation of multiple genes in cancer and how proteins such as MBD2 could orchestrate a wide net of reprogramming of the methylome and transcriptome in liver cancer that is required for cancer growth and invasiveness. These data provide strong support for MBD2 as a unique anticancer target.
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